Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528555 | 0.89 | ALDH1A1 (0.58) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL528593 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL27431445 | 0.89 | ALDH1A1 (0.55) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL10192631 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL3481182 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL27797486 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL8113842 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL17144681 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL11048095 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTMAPK1KDM4EPKM | |
| SCHEMBL20916593 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTMAPK1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 584 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143732-A | Preparation method of lenalidomide impurity A | 广州科锐特药业有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-118108699-A | Preparation method of lenalidomide | 杭州新曦科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-114076801-B | Detection method of related substances in lenalidomide | 上海博志研新药物研究有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117304169-A | Preparation method of lenalidomide | 苏州恒泽通生物科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-111196800-B | Method for preparing lenalidomide | 欣凯医药化工中间体（上海）有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-114076801-A | Method for detecting related substances in lenalidomide | 上海博志研新药物技术有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-113956189-A | Preparation method of lenalidomide impurity D | 深圳菲斯生物科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-213913765-U | 2-bromomethyl-3-nitrobenzoic acid methyl ester feeding reaction device | 苏利制药科技江阴有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-111377903-A | Preparation method of anhydrous compound of lenalidomide | 江苏豪森药业集团有限公司 | 2020-07-07 | — | — | CN | claimed |
| CN-107698484-B | Preparation method and application of lenalidomide derivative | 广东中科药物研究有限公司 | 2020-05-19 | — | — | CN | claimed |
| WO-2015057043-A1 | A PROCESS FOR THE PREPARATION OF LENALIDOMIDE | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2015-04-23 | — | — | WO | claimed |
| EP-2545043-A1 | ANHYDROUS LENALIDOMIDE FORM-I | Natco Pharma Limited (IN) | 2013-01-16 | — | — | EP | claimed |
| WO-2013005229-A1 | PROCESS FOR LENALIDOMIDE | HETERO RESEARCH FOUNDATION (IN) | 2013-01-10 | — | — | WO | claimed |
| EP-2493872-A1 | PROCESS FOR THE PREPARATION OF LENALIDOMIDE | Ranbaxy Laboratories Limited (IN) | 2012-09-05 | — | — | EP | claimed |
| US-20120184746-A1 | PROCESS FOR THE PREPARATION OF LENALIDOMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| US-20120071509-A1 | PROCESS | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2012-03-22 | — | — | US | claimed |
| EP-2403845-A2 | IMPROVED PROCESS | Generics [UK] Limited (GB) | 2012-01-11 | — | — | EP | claimed |
| WO-2011111053-A1 | ANHYDROUS LENALIDOMIDE FORM-I | NATCO PHARMA LIMITED (IN) | 2011-09-15 | — | — | WO | claimed |
| WO-2011027326-A1 | PROCESS FOR THE PREPARATION OF LENALIDOMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | claimed |
| WO-2010100476-A2 | IMPROVED PROCESS | GENERICS [UK] LIMITED (GB) | 2010-09-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071509-A1 | PROCESS | RCC1, FIP1L1, MALT1 | ALDH1A1 523/4885MAPT 821/4885MAPK1 470/4885 |
| US-20120184746-A1 | PROCESS FOR THE PREPARATION OF LENALIDOMIDE | THPO, MCL1, EPOR | ALDH1A1 303/4885MAPT 3935/4885MAPK1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.